Published in J Psychiatr Res on September 07, 1995
Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr Bull (2009) 2.98
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther (2009) 1.67
Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophr Bull (2006) 1.64
Actively paranoid patients with schizophrenia over attribute anger to neutral faces. Schizophr Res (2010) 1.00
A comparison of facial emotion processing in neurological and psychiatric conditions. Front Psychol (2012) 0.92
Functional significance of preserved affect recognition in schizophrenia. Psychiatry Res (2010) 0.88
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs. Med Sci Monit (2012) 0.84
Greater impairment in negative emotion evaluation ability in patients with paranoid schizophrenia. Yonsei Med J (2006) 0.82
Can antipsychotics improve social cognition in patients with schizophrenia? CNS Drugs (2013) 0.79
Virtual Avatar for Emotion Recognition in Patients with Schizophrenia: A Pilot Study. Front Hum Neurosci (2016) 0.75
Facial affect processing deficits in schizophrenia: a meta-analysis of antipsychotic treatment effects. J Psychopharmacol (2014) 0.75
Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry (2008) 2.07
Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry (1995) 1.39
Progression of cerebroventricular enlargement and the subtyping of schizophrenia. Psychiatry Res (1997) 0.96
Biogenic amine hypotheses of affective disorders. Life Sci (1979) 0.93
Characterization of human cleaved N-CAM and association with schizophrenia. Exp Neurol (2001) 0.91
Mentoring psychiatric trainees' first paper for publication. Acad Psychiatry (1998) 0.90
Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacologia (1976) 0.85
No evidence for linkage between chromosome 5 markers and schizophrenia. Hum Hered (1990) 0.84
Serotonin and impulsive/aggressive behavior in cocaine dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry (1994) 0.84
Pharmacokinetics of red blood cell phenothiazine and clinical effects. Acute dystonic reactions. Arch Gen Psychiatry (1976) 0.84
Depression and antidepressant therapy: receptor dynamics. Prog Neuropsychopharmacol Biol Psychiatry (1990) 0.84
Heterogeneity of the psychoses: is there a neurodegenerative psychosis? Schizophr Bull (1998) 0.83
Lithium response in good prognosis schizophrenia. Am J Psychiatry (1980) 0.82
Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. Psychiatry Res (1991) 0.82
Monoamine distribution in primate brain. I Catecholamine-containing perikarya in the brain stem of Macaca speciosa. J Comp Neurol (1975) 0.80
Beta-adrenergic receptor function in affective illness. Am J Psychiatry (1979) 0.80
Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology (Berl) (1983) 0.79
Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients. Arch Gen Psychiatry (1986) 0.79
Monoamine distribution in primate brain-IV. Indoleamine-containing perikarya in the brain stem of Macaca arctoides. Neuroscience (1982) 0.78
'Schizophrenia as a chronic active brain process ...': perhaps, but only in part. Psychiatry Res (1997) 0.78
Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. Am J Psychiatry (1977) 0.78
A biomodal distribution of plasma HVA/MHPG in the psychoses. Psychiatry Res (1997) 0.78
Phenothiazine levels in plasma and red blood cells. Their relationship to clinical improvement in schizophrenia. Arch Gen Psychiatry (1980) 0.78
Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics. Biol Psychiatry (1990) 0.77
Blood-brain barrier to 6-hydroxydopamine: uptake by heart and brain. Life Sci (1975) 0.77
Phencyclidine-induced stereotyped behavior in monkeys: antagonism by pimozide. Eur J Pharmacol (1978) 0.77
Monamine distribution in primate brain. II. Brain stem catecholaminergic pathways in Macaca speciosa (arctoides). Brain Res (1976) 0.77
Neuroleptic-induced emotional defecation: effects of scopolamine and haloperidol. Psychopharmacology (Berl) (1989) 0.77
Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Ann Clin Psychiatry (1995) 0.77
Prediction of lithium carbonate dosage in psychiatric inpatients using the repeated one-point method. Clin Pharm (1983) 0.76
Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems. Biol Psychiatry (1986) 0.76
Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol (1984) 0.76
Negative symptoms of familial schizophrenia breed true in unstable (vs. stable) cerebral-ventricle pedigrees. Schizophr Res (1999) 0.76
Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response. Prog Neuropsychopharmacol Biol Psychiatry (1991) 0.76
Growth hormone response to apomorphine and family patterns of illness. Biol Psychiatry (1987) 0.76
Physostigmine and lithium response in the schizophrenias. Am J Psychiatry (1981) 0.76
Impact of lithium therapy on core psychotic symptoms of schizophrenia. Br J Psychiatry (1984) 0.76
Progressive brain atrophy and VBR increase in schizophrenia? Acta Psychiatr Scand (2000) 0.75
CSF N-CAM in neuroleptic-naïve first-episode patients with schizophrenia. Schizophr Res (1998) 0.75
Methodological issues facing the interpretation of high-risk studies: biological heterogeneity. Schizophr Bull (1987) 0.75
Postsynaptic supersensitivity in schizophrenia. Am J Psychiatry (1977) 0.75
Schizophrenia and reduced cyclic AMP production: evidence for the role of receptor-linked events. Life Sci (1982) 0.75
Serum homovanillic acid levels in schizophrenic patients and normal control subjects. Psychiatry Res (1993) 0.75
Growth hormone response and central aminergic systems in affective diseases [proceedins]. Psychopharmacol Bull (1977) 0.75
Phenothiazine red cell levels and clinical response [proceedings]. Psychopharmacol Bull (1978) 0.75
Lithium ratio in vitro. Diagnosis and lithium carbonate response in psychotic patients. Arch Gen Psychiatry (1984) 0.75
Behavioral changes in a juvenile primate social colony with chronic administration of d-amphetamine. Psychopharmacol Commun (1976) 0.75
Growth hormone catecholamines in affective disease. Am J Psychiatry (1975) 0.75
On the physical properties of red cell ghost membranes in the affective disorders and psychoses. A fluorescence polarization study. J Affect Disord (1986) 0.75
A family study of lithium-responsive psychosis. J Affect Disord (1990) 0.75
Adrenergic-receptor desensitization and course of clinical improvement with desipramine treatment. Psychopharmacology (Berl) (1984) 0.75
Lithium ratio in vitro: familial patterns of illness. Psychiatry Res (1986) 0.75
CSF homocysteine is not elevated in schizophrenia. J Neural Transm (Vienna) (2005) 0.75
Predictors of response to lithium in patients with psychoses. Am J Psychiatry (1995) 0.75
Fluphenazine activity and antipsychotic response. Psychopharmacology (Berl) (1986) 0.75
Dopamine and non-dopamine psychoses. Psychopharmacology (Berl) (1984) 0.75
A psychobiologic perspective in treating psychiatric disorders. Compr Ther (1984) 0.75
Growth hormone levels and lithium ratios as predictors of success of lithium therapy in schizophrenia. Am J Psychiatry (1982) 0.75
Clinical relevance of thiothixene plasma levels. J Clin Psychopharmacol (1984) 0.75
Changes in urinary catecholamines and their metabolites in depressed patients treated with amitriptyline or imipramine. J Psychiatr Res (1987) 0.75
Kinetic analysis of platelet monoamine oxidase in chronic schizophrenia. Life Sci (1981) 0.75
Length of psychiatric hospitalization and prediction of antipsychotic response. Prog Neuropsychopharmacol Biol Psychiatry (1990) 0.75
Recent developments in the treatment of psychiatric disorders. Ohio State Med J (1984) 0.75
Relationship of psychotic symptom clusters in schizophrenia to neuroleptic treatment and growth hormone response to apomorphine. Psychiatry Res (1986) 0.75
TSH response to TRH and haloperidol response latency in psychoses. Biol Psychiatry (1988) 0.75
Combined thioridazine and desipramine: early antidepressant response. Psychopharmacology (Berl) (1984) 0.75
Neuroendocrine and amine studies in affective illness. Psychoneuroendocrinology (1977) 0.75
Effect of carbidopa on the metabolism of L-dopa in the pigtail monkey. Biochem Pharmacol (1976) 0.75
Down-regulation of central dopamine receptors in schizophrenia. Am J Psychiatry (1985) 0.75
Therapeutic blood levels of fluphenazine: plasma or RBC determinations? Psychopharmacol Bull (1984) 0.75
Neutropenia in a patient receiving clozapine. Am J Psychiatry (1994) 0.75
Lithium and psychosis revisited. Prog Neuropsychopharmacol Biol Psychiatry (1998) 0.75
Urinary cyclic AMP excretion by methadone subjects during gradual and acute withdrawal. Psychopharmacology (Berl) (1977) 0.75
Mood-incongruent versus mood-congruent psychosis: differential antipsychotic response to lithium therapy. Psychiatry Res (1984) 0.75
Thioridazine effect on desipramine plasma levels. J Clin Psychopharmacol (1983) 0.75
Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacol Bull (1985) 0.75
Platelet monoamine oxidase activity in the psychoses: relationship to symptoms and lithium response. Psychiatry Res (1984) 0.75
Fluphenazine plasma levels and clinical response. J Clin Psychiatry (1984) 0.75
Lithium response and psychoses: a double-blind, placebo-controlled study. Psychiatry Res (1984) 0.75